Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- LIMN
- Price
- 0.77
- Stock movement up
- +0.05 (7.62%)
- Company name
- Liminatus Pharma, Inc. Class A Common Stock
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 20.03M
- Ent value
- 22.29M
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
LIMN does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 26.01M |
| EPS (TTM) | -0.12 |
| FCF per share (TTM) | -0.08 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -542.00 |
| Operating income (TTM) | -2.24M |
| Net income (TTM) | -3.33M |
| EPS (TTM) | -0.12 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 724.50K |
| Net receivables | 0.00 |
| Total current assets | 1.20M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 1.34M |
| Accounts payable | 559.17K |
| Short/Current long term debt | 1.44M |
| Total current liabilities | 2.86M |
| Total liabilities | 2.99M |
| Shareholder's equity | -1.65M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -2.12M |
| Capital expenditures (TTM) | 13.12K |
| Free cash flow (TTM) | -2.13M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -248.42% |
| Return on Invested Capital | 1640.64% |
| Cash Return on Invested Capital | 1047.20% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.76 |
| Daily high | 0.77 |
| Daily low | 0.72 |
| Daily Volume | 70K |
| All-time high | 1.96 |
| 1y analyst estimate | - |
| Beta | 0.17 |
| EPS (TTM) | -0.12 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| LIMN | S&P500 | |
| Current price drop from All-time high | -60.71% | -0.89% |
| Highest price drop | -68.88% | -19.00% |
| Date of highest drop | 31 Dec 2025 | 8 Apr 2025 |
| Avg drop from high | -43.17% | -2.49% |
| Avg time to new high | 10 days | 6 days |
| Max time to new high | 77 days | 89 days |
COMPANY DETAILS
Marketcap
20.03M
Marketcap category
Small-cap
Description
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner